Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present TRACON Pharmaceuticals, Inc. (NASDAQ: TCON).

Full DD Report for TCON

You must become a subscriber to view this report.


Recent News from (NASDAQ: TCON)

TRACON Pharmaceuticals to Present at 2018 Wells Fargo Healthcare Conference
SAN DIEGO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced tod...
Source: GlobeNewswire
Date: August, 29 2018 16:05
TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q2 2018 Results - Earnings Call Transcript
Tracon Pharmaceuticals (TCON) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET Executives Charles Theuer - President and Chief Executive Officer Scott Brown - Director, Controller Analysts Gill Bloom - Needham & Company Jake Colby - BTIG Presentation O...
Source: SeekingAlpha
Date: August, 08 2018 22:18
Tracon misses by $0.02
Tracon (NASDAQ: TCON ): Q2 EPS of -$0.33 misses by $0.02 . More news on: Tracon Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 08 2018 16:30
TRACON Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age‐related macular degeneration, today announced financial...
Source: GlobeNewswire
Date: August, 08 2018 16:04
TRACON to Report Second Quarter 2018 Company Highlights and Financial Results on August 8, 2018
SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that it will rep...
Source: GlobeNewswire
Date: August, 01 2018 16:05
Your Daily Pharma Scoop: Wright Receives PMA, Allergan And Corbus Report Positive
Analysis Focus: WMGI Wright Medical Group N.V. ( WMGI ) stock prices climbed +4.46% to $25.78 on the news of its receipt of FDA premarket approval (‘PMA) for Augment. Augment, an injectable bone graft, is a combination product containing human platelet derived growth factor (rhPDGF...
Source: SeekingAlpha
Date: June, 15 2018 10:00
TRACON announces preclinical data from TRC105 in combination with a PD-1 antibody in murine models of colorectal cancer
TRACON Pharmaceuticals (NASDAQ: TCON ) announces  positive preclinical data from TRC105, TRACON’s endoglin antibody, in combination with a PD-1 antibody in an oral presentation at the 2018 International Cancer Microenvironment Society meeting. More news on: Tracon Pharmaceutic...
Source: SeekingAlpha
Date: June, 13 2018 09:32
TRACON Announces Presentation of Preclinical Data from Studies of TRC105 in Combination with a PD-1 Antibody in Murine Models of Colorectal Cancer
SAN DIEGO, June 13, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announc...
Source: GlobeNewswire
Date: June, 13 2018 08:00
TRACON Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that Charles Theu...
Source: GlobeNewswire
Date: May, 31 2018 16:10
TRACON Pharmaceuticals Reports Granting of Inducement Award
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a biopharmaceutical company that develops targeted therapies for cancer and wet age-related macular degeneration, announced today that it has issued an inducement award to a new executive employee. In conne...
Source: GlobeNewswire
Date: May, 31 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-082.102.152.202.07564,642
2018-05-172.502.502.552.45101,984
2017-03-104.154.054.154.051,412
2017-03-093.9514.104.153.9029,469
2017-03-083.853.954.003.8536,896

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-144,95750,7929.7594Cover
2018-12-132,57061,4384.1831Cover
2018-12-126,91774,0499.3411Cover
2018-12-114,50066,5006.7669Cover
2018-12-1062136,1981.7156Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TCON.


About TRACON Pharmaceuticals, Inc. (NASDAQ: TCON)

Logo for TRACON Pharmaceuticals, Inc. (NASDAQ: TCON)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: TCON)

      Simplified registration form
      Filing Type: S-3Filing Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 04 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 25 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 25 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 23 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: April, 11 2018
      Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
      Filing Type: DFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 10 2018

       

       


      Daily Technical Chart for (NASDAQ: TCON)

      Daily Technical Chart for (NASDAQ: TCON)


      Stay tuned for daily updates and more on (NASDAQ: TCON)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: TCON)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TCON is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TCON and does not buy, sell, or trade any shares of TCON. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/